High-Risk Smoldering Myeloma: Treating a Disease That Hasn't Caused a Symptom Yet
A single patient with high-risk smoldering myeloma and no symptoms at all. The disagreement isn't about whether a new trial changed the evidence — it did — it's about whether that evidence answers the question that actually matters to him.
V.D., a 58-year-old high school woodshop teacher, learned he had a monoclonal protein from labs drawn for a life-insurance physical. The marrow that followed showed 28% plasma cells and his involved-to-uninvolved free light chain ratio came back at 145 — two of the three Mayo 20/2/20 criteria breached, and not marginally: the model's thresholds are 20% and 20, and he is at 28% and 145, which places him not merely in the high-risk band but toward its far end, where the two-year progression estimates stop sounding like a statistic and start sounding like a schedule. Against that, he has no anemia, no renal impairment, no lytic lesions and no hypercalcemia — not one CRAB criterion, the whole traditional boundary between watching and treating. He feels entirely well and has said he was more disturbed by the word appearing in his chart than by anything his body has told him.
AQUILA was built for precisely the patient his numbers describe, and it is positive: daratumumab monotherapy meaningfully delayed progression compared with observation in high-risk smoldering disease. Progression-free survival, though, is a peculiar endpoint to hand this particular man. It measures the arrival of a diagnosis he already has, in a body that is not yet complaining, and its follow-up is not yet mature enough to say whether delaying that arrival makes him live longer or feel better. So the trial answers a question with real content — does the drug postpone the event — while leaving open the one he would actually be trading years of infusions for. His own position is not a gap in the clinical picture but a second, competing fact about him: he has said clearly that watching makes him anxious, and equally clearly that he does not want to spend years in an infusion chair for a disease that has never made him feel unwell.
Myeloma clinic, shared decision-making visit
AQUILA is a real, positive, randomized trial specifically built for high-risk smoldering disease like his, and it found daratumumab monotherapy meaningfully delayed progression to active myeloma. Waiting for CRAB criteria to appear means waiting for organ damage to accumulate before acting on evidence we already have.
Delaying progression and extending survival are not the same claim, and AQUILA's own follow-up hasn't yet shown the second one. He'd be starting years of monoclonal antibody therapy — real infusion-reaction risk, real infection risk, real cost — against a surrogate endpoint that, however statistically robust, hasn't yet been shown to change how long or how well he lives.
A trial being positive on its primary endpoint doesn't automatically answer whether that endpoint is the one that should drive a treatment decision for an entirely asymptomatic patient.
I don't think the clinical evidence alone settles this, and I don't think it's supposed to. He's told me directly that watching and waiting makes him anxious in a way that affects his daily life — and, in the same conversation, that he doesn't want to commit to years of infusions and monitoring for a disease that currently causes him nothing. Both of those are real inputs only he can weigh, not gaps in the clinical picture for us to close.
Not agreed, and left genuinely unresolved rather than smoothed into a recommendation: the hematologist-oncologist's read that a positive randomized trial in his exact risk category is reason enough to treat now, against the clinical pharmacologist's read that a progression-delay endpoint alone doesn't yet justify years of therapy in an asymptomatic patient.
What was agreed was the actual decision in front of him today: close surveillance for now, with daratumumab presented as a standing option he can choose whenever he wants it, not one gated behind a clinical trigger he hasn't yet met.